Welcome to our dedicated page for Immunocore Holdings plc news (Ticker: $IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunocore Holdings plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunocore Holdings plc's position in the market.
Immunocore presented new clinical data for KIMMTRAK at the 2024 ASCO Annual Meeting. The data showed that patients with unresectable or metastatic uveal melanoma who had stable disease and confirmed tumor reduction experienced similar clinical outcomes to those with a partial response. The Phase 2 trial indicated that 25% of 127 patients had any tumor reduction, including 6 partial responses. In the Phase 3 trial, the durability of tumor reduction was similar for patients with stable disease and partial response, both lasting 11 months. This reinforces KIMMTRAK as a standard treatment for HLA-A*02:01-positive patients.
Immunocore has released updated Phase 1 data for brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients. The study showed promising disease control rates, progression-free survival (PFS), and molecular responses, particularly in PRAME positive patients. Brenetafusp was well tolerated as a monotherapy and in combination with anti-PD1. The Phase 3 clinical trial (PRISM-MEL-301) is now enrolling patients for first-line advanced cutaneous melanoma treatment. Detailed results will be presented at the ASCO 2024 meeting.
Immunocore, a Nasdaq-listed commercial-stage biotech firm specializing in immunomodulating medicines for cancer, infectious and autoimmune diseases, announced its participation in the Jefferies Global Healthcare Conference.
The event is scheduled for June 6, 2024, at 2:30 p.m. EDT.
A live webcast of the presentation will be available on the Immunocore website, with a replay accessible post-event.
Immunocore has announced the conversion of its Phase 2/3 TEBE-AM trial into a registrational Phase 3 trial to evaluate KIMMTRAK (tebentafusp-tebn) for previously treated advanced cutaneous melanoma. Following FDA consultation, all patients from the Phase 2/3 trial will be included in the Phase 3 intent-to-treat population. The Phase 3 trial will continue with three arms: KIMMTRAK monotherapy, KIMMTRAK with pembrolizumab, and a control.
This decision is expected to accelerate the time to the final overall survival analysis. The conversion was motivated by KIMMTRAK’s promising results in uveal melanoma and Phase 1 cutaneous melanoma trials. The Phase 1b study showed that KIMMTRAK, combined with checkpoint inhibitors, had a one-year overall survival rate of approximately 75% in patients with metastatic cutaneous melanoma.
Immunocore reported first quarter financial results with KIMMTRAK® net revenues of $70.3 million in Q1 2024. The company continues to expand global access with 7 additional launches since January 2024. Phase 1/2 brenetafusp clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024. Financially, the company saw a 36% increase in net product revenue, with total revenue reaching $70.3 million in Q1 2024. However, research & development expenses also grew, resulting in a net loss for the quarter. Cash and cash equivalents stood at $832.8 million as of March 31, 2024.